High EMP3 expression predicts poor outcomes in HER2-enriched breast cancer, indicating potential treatment challenges.
High EMP3 expression in HER2-enriched breast cancer predicts poor patient outcomes. Overexpression of EMP3 exerts an upregulatory effect on the PI3K-AKT pathway and boosts the development of trastuzumab resistance.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: